Can-Fite BioPharma Ltd. Long-Term Debt 2011-2026 | CANF

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Quarterly Long-Term Debt Can-Fite BioPharma Ltd.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	71 K	-	25 K	-	24 K	-	22 K	-	39 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
71 K	22 K	36.2 K

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
Biohaven Pharmaceutical Holding Company Ltd. BHVN	627 M	$ 9.13	-0.76 %	$ 591 M	USA
MorphoSys AG MOR	273 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	68.2 M	-	-	$ 866 M	China
Midatech Pharma plc MTP	4.76 M	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
Aptorum Group Limited APM	130 K	$ 0.91	2.42 %	$ 6.69 M	China
Edesa Biotech EDSA	19.8 K	$ 15.52	-2.39 %	$ 49.6 M	USA
Biophytis SA BPTS	1.83 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	173 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	42 M	$ 22.47	1.19 %	$ 3.72 B	USA
EyeGate Pharmaceuticals, Inc. EYEG	278 K	-	-1.52 %	$ 24.7 M	USA
Applied Molecular Transport AMTI	49 K	-	-	$ 10.1 M	USA
Fortress Biotech FBIO	52.4 M	$ 2.24	0.9 %	$ 62.5 M	USA
Galectin Therapeutics GALT	20 K	$ 2.26	0.22 %	$ 144 M	USA
Advaxis ADXS	8.14 M	-	-9.65 %	$ 45.9 M	USA
Grifols, S.A. GRFS	5.9 B	$ 8.2	3.6 %	$ 6.83 B	Spain
Harmony Biosciences Holdings HRMY	144 M	$ 31.01	-0.13 %	$ 1.78 B	USA
Институт стволовых клеток человека ISKJ	175 M	-	-	-	Russia
ImmuCell Corporation ICCC	7.49 M	$ 8.44	-	$ 76.2 M	USA
InflaRx N.V. IFRX	331 K	$ 1.95	-1.77 %	$ 152 M	Germany
Immuron Limited IMRN	175 K	$ 0.83	3.44 %	$ 6.55 M	Australia
Incyte Corporation INCY	30.2 M	$ 98.87	-0.23 %	$ 19.3 B	USA
InMed Pharmaceuticals INM	16 K	$ 0.71	1.28 %	$ 1.74 M	Canada
INmune Bio INMB	411 K	$ 1.35	1.5 %	$ 33.4 M	USA
Innoviva INVA	258 M	$ 23.13	0.35 %	$ 1.56 B	USA
Aeterna Zentaris AEZS	31 K	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	2.95 M	-	-10.17 %	$ 12.2 K	USA
Brainstorm Cell Therapeutics BCLI	171 K	-	-2.5 %	$ 5.88 M	USA
BioNTech SE BNTX	231 M	$ 104.54	2.92 %	$ 27.2 B	Germany
Aeglea BioTherapeutics AGLE	4 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	9.12 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	2.29 M	-	1.93 %	$ 17.4 M	USA
Jaguar Health JAGX	892 K	$ 7.55	-4.13 %	$ 17.6 M	USA
KalVista Pharmaceuticals KALV	172 M	$ 26.67	-0.02 %	$ 1.44 B	Britain
Akero Therapeutics AKRO	529 K	-	-	$ 3.67 B	USA
Innate Pharma S.A. IPHA	16.9 M	$ 1.43	-4.03 %	$ 235 M	France
Kamada Ltd. KMDA	36 K	$ 8.15	0.49 %	$ 260 M	Israel
Akouos AKUS	28.3 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	38.2 M	-	-	$ 28.6 M	USA
AlloVir ALVR	1.13 M	-	4.14 %	$ 49.1 M	USA
Ligand Pharmaceuticals Incorporated LGND	49 K	$ 223.98	-0.39 %	$ 4.1 B	USA
Liquidia Corporation LQDA	19.9 M	$ 38.39	0.62 %	$ 3.3 B	USA
Ampio Pharmaceuticals AMPE	274 K	-	-11.43 %	$ 502 K	USA
CureVac N.V. CVAC	25.4 M	-	-	$ 867 M	Germany
Applied Therapeutics APLT	38 K	-	-	$ 8.42 M	USA
Aptose Biosciences APTO	193 K	-	-45.71 %	$ 1.2 M	Canada
Aquestive Therapeutics AQST	45 M	$ 4.08	0.74 %	$ 436 M	USA